{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:20:59Z","timestamp":1790706059556,"version":"4.1.0"},"reference-count":20,"publisher":"The Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Context: Bisphosphonate-related osteonecrosis (BON) of the jaws is a newly identified condition for which the exact mechanism involved in its pathogenesis remains obscure.<\/jats:p>\n                  <jats:p>Objective: The objective of the study was to evaluate whether diabetes mellitus (DM) may be a contributing factor in the development of BON.<\/jats:p>\n                  <jats:p>Design: From 2004 to 2006, 31 patients were diagnosed with BON. The diagnosis of BON was based on the medical and dental history of each patient as well as the observation of clinical signs and symptoms of this pathological process. DM was based on two consecutive fasting blood glucose levels above 7 mmol\/liter.<\/jats:p>\n                  <jats:p>Setting: The study was completed in the Hebrew University-Hadassah Hospital referral center.<\/jats:p>\n                  <jats:p>Results: Of the 31 patients with BON, 18 (58%) were found to have DM or impaired fasting glucose. The proportion of diabetic patients was much higher than expected relative to the incidence of DM in the general population (14%) and compared with the proportion of diabetic patients in a control group of oncological patients treated with bisphosphonates and without BON (12%) (P = 0.00003).<\/jats:p>\n                  <jats:p>Conclusions: This finding indicates that DM may be a risk factor for BON and that DM patients treated with bisphosphonates should be carefully monitored. We discuss here the bone metabolic pathways characteristic of DM patients and the way in which these pathways can augment the effects of bisphosphonates.<\/jats:p>","DOI":"10.1210\/jc.2006-2036","type":"journal-article","created":{"date-parts":[[2006,12,19]],"date-time":"2006-12-19T22:08:28Z","timestamp":1166566108000},"page":"1172-1175","source":"Crossref","is-referenced-by-count":156,"title":["Possible Association between Diabetes and Bisphosphonate-Related Jaw Osteonecrosis"],"prefix":"10.1210","volume":"92","author":[{"given":"Mogher","family":"Khamaisi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine B and the Diabetes Center (M.K., E.L., I.R.), Hebrew University-Hadassah Medical Center, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Regev","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery (E.R.), Hadassah Medical Center, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Yarom","sequence":"additional","affiliation":[{"name":"Department of Oral Pathology and Oral Medicine (N.Y.), The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batia","family":"Avni","sequence":"additional","affiliation":[{"name":"Department of Department of Hematology (B.A., S.E.), Hadassah Medical Center, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Leitersdorf","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine B and the Diabetes Center (M.K., E.L., I.R.), Hebrew University-Hadassah Medical Center, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itamar","family":"Raz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine B and the Diabetes Center (M.K., E.L., I.R.), Hebrew University-Hadassah Medical Center, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Elad","sequence":"additional","affiliation":[{"name":"Department of Oral Medicine (S.E.), Hebrew University-Hadassah School of Dental Medicine, Hadassah Medical Center, Jerusalem 91120, Israel"},{"name":"Department of Department of Hematology (B.A., S.E.), Hadassah Medical Center, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071613290506800_R1","first-page":"2226","article-title":"Osteoporosis","author":"Lindsay","year":"2001","journal-title":"In: Braunwald EFA, Kasper DL, Hauser SL, Long DL, Jameson JL, eds. Harrison\u2019s principles of internal medicine. New York: McGraw-Hill;"},{"key":"2020071613290506800_R2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.joms.2003.11.003","article-title":"Bisphosphonates and bone necrosis.","volume":"62","author":"Pogrel","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"2020071613290506800_R3","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0278-2391(03)00328-8","article-title":"Osteonecrosis of the jaws associated with cancer chemotherapy.","volume":"61","author":"Wang","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"2020071613290506800_R4","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"2020071613290506800_R5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates.","volume":"353","author":"Woo","year":"2005","journal-title":"N Engl J Med"},{"key":"2020071613290506800_R6","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"2020071613290506800_R7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates.","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"key":"2020071613290506800_R8","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"2020071613290506800_R9","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.14219\/jada.archive.2005.0108","article-title":"Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper.","volume":"136","author":"Migliorati","year":"2005","journal-title":"J Am Dent Assoc"},{"key":"2020071613290506800_R10","unstructured":"2002 Osteomyelitis. In: Neville BW, Damm DD, Allen CM, Bougout JE, eds. Oral and maxillofacial pathology. 2nd ed. Philadelphia: W. B. Saunders Co."},{"key":"2020071613290506800_R11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0002-9610(99)00050-1","article-title":"The effects of peripheral vascular disease with osteomyelitis in the diabetic foot.","volume":"177","author":"Hill","year":"1999","journal-title":"Am J Surg"},{"key":"2020071613290506800_R12","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1464-5491.2005.01543.x","article-title":"Impaired vascular function during short-term poor glycaemic control in type 1 diabetic patients.","volume":"22","author":"Sorensen","year":"2005","journal-title":"Diabet Med"},{"key":"2020071613290506800_R13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/dmrr.449","article-title":"Skeletal involvement in patients with diabetes mellitus.","volume":"20","author":"Carnevale","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"key":"2020071613290506800_R14","first-page":"17","article-title":"Bone metabolic abnormality in diabetes, especially about osteoblast dysfunction.","volume":"16","author":"Kumeda","year":"2006","journal-title":"Clin Calcium"},{"key":"2020071613290506800_R15","doi-asserted-by":"crossref","first-page":"E735","DOI":"10.1152\/ajpendo.00159.2005","article-title":"Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues","volume":"289","author":"Thrailkill","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2020071613290506800_R16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00004045-200504000-00009","article-title":"Oral manifestations of diabetes.","volume":"23","author":"Stegeman","year":"2005","journal-title":"Home Health Nurse"},{"key":"2020071613290506800_R17","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/S0002-9440(10)63239-7","article-title":"Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.","volume":"165","author":"Yamagishi","year":"2004","journal-title":"Am J Pathol"},{"key":"2020071613290506800_R18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/rheumatology\/kei149","article-title":"Oxidative stress by glutathione depletion induces osteonecrosis in rats.","volume":"45","author":"Ichiseki","year":"2005","journal-title":"Rheumatology (Oxf)"},{"key":"2020071613290506800_R19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/pds.1229","article-title":"Prevalence of glucose metabolism abnormalities and cardiovascular co-morbidity in the U.S. elderly adult population.","volume":"15","author":"Varas-Lorenzo","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2020071613290506800_R20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1464-5491.2005.01787.x","article-title":"Diabetes prevalence in England, 2001\u2014estimates from an epidemiological model.","volume":"23","author":"Forouhi","year":"2006","journal-title":"Diabet Med"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/3\/1172\/9056368\/jcem1172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/3\/1172\/9056368\/jcem1172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T19:55:34Z","timestamp":1594929334000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/92\/3\/1172\/2598063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,1]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2006-2036","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1087413.540450","asserted-by":"object"}]},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,1]]}}}